Presented by GEN, Produced with Support from Lonza
The therapeutic potential of the genome editing system CRISPR-Cas9 has ignited the imaginations of basic science and clinical researchers. It seems that almost every day investigators are developing innovative ways to utilize the gene editing technology as an intervention for treating a vast array of diseases. As this cutting-edge science rapidly advances, it is important for researchers to have a firm grasp on appropriate target validation techniques and scalable methodologies that will allow CRISPR technology to progress efficiently.
Speakers:
- Shondra Miller, Ph.D. Director/Assistant Member Center for Advanced Genome Engineering (CAGE), St. Jude Children’s Research Hospital
- Alexander Marson, M.D., Ph.D. Assistant Professor UCSF School of Medicine
You Will Learn:
- How various site-specific nuclease validation assays compare when determining the efficiency of the CRISPR-Cas9 system
- Modalities for incorporating CRISPR into primary human cells, along with techniques for effective scale-up
CRISPR Transfection:
- Efficient Genome Editing using Lonza's NucleofectorTM Technology
